Abstract: Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.

Abstract: The present invention provides an aptamer binding to NGF and capable of forming a potential secondary structure represented by the formula (I): wherein N is one nucleotide selected from the group consisting of A, G, C, U and T, N11-N13, N21-N23, N32-N38 and N42-N48 are the same or different and each is a bond or 1 or 2 nucleotides selected from the group consisting of A, G, C, U and T, N14, N24, N31, N41, N39 and N49 are the same or different and each is one nucleotide selected from the group consisting of A, G, C, U and T, N14 and N24, N31 and N41, and N39 and N49 each form a Watson-Crick base pair, N11-N12-N13-N14 and N21-N22-N23-N24 are nucleotide sequences capable of forming a stem structure in combination, and N31-N32-N33-N34-N35-N36-N37-N38-N39 and N41-N42-N43-N44-N45-N46-N47-N48-N49 are nucleotide sequences capable of forming a stem structure in combination.

Abstract: With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.

Abstract: Provided is a higher quality aptamer having a binding activity to NGF. An aptamer binding to NGF, which satisfies the following (1) and (2): (1) containing the sequence represented by UGAAARAAACC (SEQ ID NO: 64) or CGAAMRAAACU (SEQ ID NO: 65), and (2) having a base length of not more than 73.

Abstract: N-Cyano-N',S-ethylene-N'-([4-methyl-5-imidazolyl)methyl]isothiourea which is of value as an intermediate in the production of cimetidine and a process for its production are provided.

Abstract: N-Cyano-N'-methyl-N"-(2-mercaptoethyl)-N"-[(4-methyl-5-imidazolyl)methyl]gu anidine and a method of producing the same are provided.

Abstract: A pharmacologically active cyanoguanidine derivative, generally referred to as cimetidine, is prepared by causing 4-methyl-5-hydroxymethylimidazole or a salt thereof to react with 2-substituted-1-methyl pyridinium salt and then causing the intermediate reaction product to react with N-cyano-N'-methyl-N"-(2-melcaptoethyl)-guanidine. The initial and subsequent reactions are carried out at room temperature under atmospheric pressure, using one and the same reaction vessel. No isolation of the intermediate reaction product resulting from the first reaction is required preparatory to the subsequent reaction. The recovery of the final intended product is carried out without using a column chromatography.